Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea

Schizophrenia Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01477918
• Other study ID #: MetS_1005
• Status: Not yet recruiting
• Phase: N/A
• First received: November 20, 2011
• Last updated: November 22, 2011
• Start date: December 2011

Study information

• Verified date: November 2011
• Source: Asan Medical Center
• Contact: Yeon-Ho Joo, Ph.D.
• Phone: 82-2-3010-3412
• Email: jooyh[@]amc.seoul.kr
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The aim of this study is to examine the prevalence of the Metabolic syndrome(MetS) in Korean patients with schizophrenia.

Primary objective:

• To investigate the prevalence of the MetS in Korean patients with schizophrenia

Secondary objectives:

• To compare the prevalence of the MetS among 3 groups according to antipsychotics: typical antipsychotic monotherapy group, atypical antipsychotic monotherapy group, 2 or more antipsychotics group (polypharmacy)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of schizophrenia according to DSM-IV-TR

• Age between 18-65 years

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X
• Schizophrenia

Locations

Country	Name	City	State
Korea, Republic of	Asan medical center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence of metabolic syndrome (MetS)	MetS will be diagnosed according to NCEP ATP III with the Asian-Pacific abdominal obesity criterion (=90 cm in men, =85 cm in women); 3 or more of the following criteria; fasting plasma glucose >= 100 mg/dl or drug use to treat elevated glucose; serum triglyceride (TG) >= 150 mg/dl or drug use to treat elevated TG; HDL cholesterol level < 40mg /dl in males, < 50 mg/dl in female or drug use to treat low HDL; Systolic BP >=130 mmHg, diastolic BP >=85 or drug use to treat hypertension; Abdominal obesity : above described		No